70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup

Abstract

TIS, an anti-PD-1 antibody, + chemo as 1L therapy demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) vs placebo (PBO) + chemo in patients (pts) with advanced or metastatic ESCC, with a manageable safety profile, at interim analysis of the Phase 3 RATIONALE-306 study. We report data from the Asia subgroup.